Sida Niu, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.1% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Sumitomo Pharma America, Inc. at 27.8% of the total. 2025 is the largest year on record at $1,166, more than ten times the $19 reported in 2020.
Across 132 payments — averaging $27.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$1K
- Astellas Pharma US Inc$359
- Procept Biorobotics Corporation$262
- Johnson & Johnson$191
- Boston Scientific$191
- Palette Life Sciences, Inc.$184
- plus $1K from 23 others
Across 7 payments — averaging $11,650 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Olympus Corporation Of The Americas$74K
- Gyrus ACMI, Inc.$8K
What the payments were for
- Food & beverage$3,28791%
- Education$3209%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 63 | $1,002 |
| Astellas Pharma US Inc | 9 | $359 |
| Procept Biorobotics Corporation | 2 | $262 |
| Johnson & Johnson | 4 | $191 |
| Boston Scientific | 4 | $191 |
| Palette Life Sciences, Inc. | 1 | $184 |
| Calyxo, Inc. | 2 | $181 |
| Axonics, Inc. | 4 | $150 |
| Intuitive Surgical | 2 | $150 |
| Dendreon Pharmaceuticals LLC | 5 | $123 |
| Verity Pharmaceuticals Inc. | 7 | $121 |
| Merck | 1 | $120 |
| Novartis | 4 | $88 |
| Urogen Pharma, Inc. | 3 | $60 |
| Medtronic | 3 | $47 |
| Tolmar, Inc. | 2 | $46 |
| Amgen | 2 | $39 |
| Bayer | 2 | $38 |
| Bluewind Medical | 1 | $37 |
| AstraZeneca | 1 | $35 |
| AbbVie | 2 | $33 |
| Olympus America Inc. | 1 | $22 |
| Travere Therapeutics, Inc. | 1 | $22 |
| Accord Healthcare, Inc. | 1 | $21 |
| Cure Medical LLC | 1 | $19 |
| Antares Pharma, Inc. | 1 | $18 |
| Progenics Pharmaceuticals, Inc. | 1 | $18 |
| Pfizer | 1 | $16 |
| Cook Medical LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORGOVYX$334
- AquaBeam Robotic System$262
- CVAC Aspiration System$156
- RYBREVANT$144
- CARVYKTI$144
- Axonics$122
- KEYTRUDA$120
- Da Vinci Surgical System$116
How this compares
$3,607 in reported general payments places this provider in the 55th percentile of 79 urology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 159 | $84,196 |
| GemtesaVibegron | 86 | $41,209 |
| Tamsulosin Hcl | 336 | $4,659 |
| Estradiol | 29 | $2,164 |
| Oxybutynin Chloride ErOxybutynin Chloride | 67 | $1,677 |
| Potassium Citrate ErPotassium Citrate | 15 | $1,473 |
| Trospium Chloride ErTrospium Chloride | 13 | $1,395 |
| Cefpodoxime Proxetil | 30 | $1,227 |
| Finasteride | 66 | $635 |
| Oxybutynin Chloride | 95 | $526 |
| NitrofurantoinNitrofurantoin Macrocrystal | 15 | $348 |
| Ciprofloxacin Hcl | 46 | $190 |
| Levofloxacin | 25 | $88 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 22 | $74 |
| Fluconazole | 20 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $359 | $84,196159 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $1,002 | $41,20986 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 79 urology providers in Nebraska.
Other urology in Omaha
- John BishayOmaha$138K
- Rebecca McCreryOmaha$71K
- Judson DaviesOmaha$67K
- Stefanie BolteOmaha$59K
- Michael FeloneyOmaha$29K
- Andrew TrainerOmaha$12K
- Stephen LeslieOmaha$12K
- Jon MortonOmaha$11K
- Brett HillOmaha$11K
- John HorganOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.